Hello Part-time Trader…👋

Premium Stock Alerts is here with your pre-market cheat sheet. In today's issue, we delve into:

• Fed's Latest Announcements: Understand the Federal Reserve's recent decisions and economic outlook, and how they might influence the markets.

• Volume Anomalies: Identify stocks witnessing unusual trading volumes, pointing to potential opportunities or risks.

• Top Pre-Market Movers: Identify early winners poised for a strong market opening.

• Market Indices & Sector Overview: Get a snapshot of key market indices and sector performances to gauge the day's potential trends.

• FDA Approvals & Upcoming Decisions: Keep an eye on the latest FDA approvals and crucial upcoming decisions affecting biotech and pharmaceutical stocks.

Now, let's dive into today's edition for a closer look at the insights and analysis that will shape your trading decisions.

Happening Today

✓ 10:30 AM ET – Crude Oil Inventories

✓ 10:30 AM ET – Cushing Crude Oil Inventories

✓ 01:00 PM ET – 7-Year Note Auction

✓ 06:00 PM ET – Fed Waller Speaks

PREMARKET SNAPSHOT 📈

Market futures hint at a modest downturn: S&P 500 -0.28%, Dow Jones -0.08%, NASDAQ 100 -0.42%.

SECTOR SNAPSHOT ✨

Most sectors see red, with Information Technology and Energy leading the decline.

Unusual Volume

📈 C3is Inc (CISS) jumped 36.65% to $0.05 on a whopping 599.69 million shares traded after it announced unaudited financial and operating results for the fourth quarter and twelve months ended December 31, 2023.

📈 Investors went wild, sending KULR Technology Group Inc (KULR) stock soaring 30.36% to $0.42 on a massive volume of 87.75 million shares after the company released that it has received a six-figure contract from Lockheed Martin (NYSE: LMT) for developing phase change material ("PCM") heat sinks that are pivotal for the thermal regulation of essential electronics within long-range precision missiles.

📈 Abnormal activity shook Opgen Inc (OPGN), pushing it up 57.89% to $0.75 on a whopping 77.67 million shares traded after announcing acquisition of preferred stock by David Lazar.

📈 WiSA Technologies Inc (WISA) stock recently closed -20.21% lower at $0.02 on substantial volume of 74.65 million shares. This unusual activity came after the company announced pricing of $2.3 million registered direct offering and concurrent private placement priced at-the-market.

📈 Mesoblast Ltd ADR (MESO) increase by 78.64% in a single trading session, with abnormally high trading volume of 69.18 million shares following the news that U.S. FDA has informed the company that following additional consideration the available clinical data from its Phase 3 study MSB-GVHD001 appears sufficient to support submission of the proposed Biologics License Application (BLA).

Premarket Movers

iBio, Inc. (IBIO) experiences a substantial 85.22% surge in pre-market trading after announcing that it has entered into a collaboration agreement with AstralBio, Inc. to discover, engineer and develop novel antibodies to treat obesity and other cardiometabolic conditions.

MariaDB plc (MRDB) sees a significant 82.17% increase, reaching a pre-market price of $0.41 after Progress Software Corp. (PRGS) confirmed that it is considering a possible offer for all the issued and to be issued share capital of MariaDB plc at a value of $0.60 per share.

PaySign, Inc. (PAYS) demonstrates a noteworthy 25.44% surge, with a pre-market price of $4.24. The company reported fourth quarter and full-year 2023 financial results.

Important FDA 

Recently Announced

Merck & Co Inc. (MRK) achieved a significant milestone with the FDA's approval of Sotatercept-csrk, marketed as WINREVAIR, for the treatment of adult patients grappling with pulmonary arterial hypertension. This approval, granted on March 26, 2024, represents a leap forward in addressing a condition with limited treatment options.

Orchard Therapeutics plc (ORTX) celebrated a significant victory with the FDA's approval of OTL-200, known as Lenmeldy, for the treatment of children suffering from metachromatic leukodystrophy. This milestone, achieved on March 18, 2024.

Announcing Today

Akebia Therapeutics, Inc. (AKBA) eagerly awaits the FDA's decision on Vadadustat's resubmitted New Drug Application (NDA), slated for March 27, 2024. This decision holds immense promise in addressing anemia due to chronic kidney disease (CKD) in adult patients undergoing dialysis.

Upcoming this Week

VANDA PHARMACEUTICALS (VNDA) is on the brink of a significant development as it awaits the FDA's decision on April 2, 2024, regarding the expanded use of Fanapt. This decision carries substantial implications for the treatment landscape of bipolar I disorder in adults.

🎁 Looking for More? Check out these complementary newsletters for diverse perspectives:

Happy investing,

Maeve Grace
Editor In Cheif
Premium Trade Alerts

 Important: This newsletter does not provide investment advice. The stocks mentioned should not be taken as recommendations. Your investments are solely your decisions.

Disclosure: I hold no positions in any companies mentioned, either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I have no business relationship with any company whose stock is mentioned in this article.Hidden Gems Unearthed! Beat the Market Today! (